HOME - Clinical cases - Periodontology
 
 
15 April 2026

Topical administration of simvastatin recovers alveolar bone loss in rats


Background and Objective

Simvastatin, a cholesterol-lowering drug, has been reported to show anabolic effects on bone metabolism. We examined the effects of simvastatin in vitro using cultured rat calvaria cells and in vivo using periodontitis-induced rats.

Material and Methods

Alkaline phosphatase activity and bone nodule formation were measured in cultured rat calvaria cells. Nylon ligature was placed around the maxillary molars of Fischer male rats for 20 d to induce alveolar bone resorption. After ligature removal, simvastatin was topically injected into the buccal gingivae for 70 d and then microcomputed tomography and histological examinations were performed.

Results

Simvastatin maintained high alkaline phosphatase activity and increased bone nodule formation in rat calvaria cells in a dose-dependent manner, showing that simvastatin increased and maintained a high level of osteoblastic function. Microcomputed tomography images revealed that treatment with simvastatin recovered the ligature-induced alveolar bone resorption, showing a 46% reversal of bone height. Histological examination clarified that low-mineralized alveolar bone was formed in simvastatin-treated rats.

Conclusion

These findings demonstrate that simvastatin has the potential to stimulate osteoblastic function and that topical administration of simvastatin may be effective for the recovery of alveolar bone loss in rats.


Authors: H. Seto, H. Ohba, K. Tokunaga, H. Hama, M. Horibe, T. Nagata
Source: https://onlinelibrary.wiley.com/

Related articles

Researchers aimed to determine if the local application of simvastatin, combined with minimally invasive papilla reflection and root planing, is effective in improving clinical attachment level,...


Read more

George Freedman gives readers a brief summary of products that have re­cent­ly been in­troduced to den­tistry, based on his clinical experience.


Partnership leverages BioHorizons’ commercial network to broaden availability of Xtant’s allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand


(“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, recently announced several key initiatives to support the drive toward ca


The forerunner of what’s now Texas A&M College of Dentistry opened 120 years ago in Dallas with the mission of educating dentists to provide quality care to patients in North Texas


This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...


 
 
 
 

 
 
 
 

Most popular

 
 

Events